Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
1.930
+0.050 (2.66%)
At close: Mar 28, 2025, 4:00 PM
1.905
-0.025 (-1.28%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Taysha Gene Therapies Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Taysha Gene Therapies stock have an average target of 6.63, with a low estimate of 5.00 and a high estimate of 8.00. The average target predicts an increase of 243.52% from the current stock price of 1.93.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 27, 2025.
Analyst Ratings
The average analyst rating for Taysha Gene Therapies stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +210.88% | Feb 27, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +262.69% | Feb 26, 2025 |
| Needham | Needham | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +210.88% | Jan 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $6 → $8 | Strong Buy | Maintains | $6 → $8 | +314.51% | Nov 15, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +262.69% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
5.76M
from 8.33M
Decreased by -30.85%
Revenue Next Year
4.07M
from 5.76M
Decreased by -29.38%
EPS This Year
-0.39
from -0.36
EPS Next Year
-0.42
from -0.39
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.8M | 11.4M | 85.1M | ||
| Avg | 5.8M | 4.1M | 44.6M | ||
| Low | n/a | n/a | 7.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 89.0% | 98.6% | 1,990.5% | ||
| Avg | -30.9% | -29.4% | 996.4% | ||
| Low | - | - | 94.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|
| High | -0.33 | -0.38 | -0.24 | |
| Avg | -0.39 | -0.42 | -0.23 | |
| Low | -0.47 | -0.56 | -0.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.